EGFRvIII-synNotch-CAR-T-cells therapy

N/A

Report date: 2022/07/01 15:29:28

Base Information

Drug NameEGFRvIII-synNotch-CAR-T-cells therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-EGFRvIII

TargetsEpidermal growth factor receptor variant III

Therapy Area/IndicationsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California, San Francisco Foundation

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, San Francisco Foundation

Inactive CompaniesN/A

Active IndicationsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A